C17orf100

Across TCGA pan-cancer cohorts, C17orf100 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C17orf100 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C17orf100 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C17orf100 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where C17orf100 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.279	0.633	.027	15	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.762	.024	12	view →
LSCC	OS	Tertile	All	1.000	0.495	.027	8	view →
GBM	OS	Median	All	0.391	0.632	.032	4	view →
LUAD	OS	Median	III,IV	0.230	0.819	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C17orf100–PDAC (DFS)

Open the PDAC breakdown →